公开(公告)号：US20190338247A1

公开(公告)日：2019-11-07

申请号：US16478477

申请日：2018-01-18

Applicant: Yeda Research And Development Co. Ltd.

Inventor： Yair REISNER ,  Esther BACHAR-LUSTIG ,  Shlomit REICH-ZELIGER

IPC: C12N5/0783 ,  C07K14/725 ,  C12N5/00 ,  A61K35/17 ,  A61P35/04 ,  A61P35/00 ,  A61P35/02 ,  C07K16/32 ,  C07K16/30 ,  C07K16/28

Abstract: An isolated cytotoxic T-lymphocyte (CTL), said CTL being a tolerance inducing cell and substantially depleted of alloreactivity, and wherein said CTL does not comprise a central memory T-lymphocyte (Tcm) phenotype, the CTL being transduced to express a cell surface receptor comprising a T cell receptor signaling module, is disclosed. Methods of generating same and using same are also disclosed.

公开(公告)号：US20220241331A1

公开(公告)日：2022-08-04

申请号：US17612279

申请日：2020-05-19

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yardena SAMUELS ,  Shelly KALAORA ,  Aviyah PERI ,  Nir FRIEDMAN ,  Shlomit REICH-ZELIGER ,  Erez GREENSTEIN

IPC: A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K14/82 ,  C12N5/0783

Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of T cells expressing a T cell receptor (TCR) having a CDR3 amino acid sequence selected from the group consisting of 199-210.

公开(公告)号：US20180200300A1

公开(公告)日：2018-07-19

申请号：US15873943

申请日：2018-01-18

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Esther BACHAR-LUSTIG ,  Shlomit REICH-ZELIGER

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  A61K35/28 ,  A61K39/395

CPC classification number: A61K35/17 ,  A61K35/28 ,  A61K39/39566 ,  A61P35/00 ,  C07K16/2812 ,  C07K16/2815

Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of tolerance inducing anti-third party cytotoxic T-lymphocytes (CTLs), wherein the tolerance inducing anti-third party CTLs are generated by directing T-lymphocytes of a donor against a third party antigen or antigens, the tolerance inducing anti-third party CTLs being substantially depleted of T-lymphocytes capable of developing into alloreactive CTLs, and wherein the tolerance inducing anti-third party CTLs do not comprise cells having a central memory T-lymphocyte (Tcm) phenotype, wherein the cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.

公开(公告)号：US20170174764A1

公开(公告)日：2017-06-22

申请号：US15127023

申请日：2015-03-26

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irun R. COHEN ,  Nir FRIEDMAN ,  Asaf MADI ,  Eric SHIFRUT ,  Shlomit REICH-ZELIGER ,  Asaf PORAN

IPC: C07K16/28

CPC classification number: C07K16/2809 ,  A61K39/0008 ,  A61K2039/505

Abstract: The present invention provides isolated peptides derived from TCR CDR3 segments, antibodies which recognize them, pharmaceutical compositions comprising them and methods of their use for modulating self-immunity.